Investigating a new treatment for laryngotracheal stenosis using mTOR inhibition
Targeting mTOR regulation of T-lymphocytes and fibroblasts in Laryngotracheal Stenosis
This study is looking at new ways to treat laryngotracheal stenosis (LTS) by exploring how a special pathway in the body can help improve the cells involved in this condition, and it will test a new type of stent that delivers treatment right where it's needed, all to help people with LTS feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10832518 on NIH RePORTER |
What this research studies
This research focuses on understanding the mechanisms behind laryngotracheal stenosis (LTS) and exploring innovative treatment options. The principal investigator, Dr. Alexander Hillel, will study how targeting the mTOR pathway can affect T-lymphocytes and fibroblasts involved in LTS. The approach includes both laboratory experiments on human cells and testing in a mouse model to evaluate the effectiveness of a novel drug-eluting stent that delivers treatment directly to the affected area. By combining insights from patient participation and advanced biomaterials, the research aims to improve outcomes for individuals suffering from this condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with laryngotracheal stenosis who may benefit from innovative treatment approaches.
Not a fit: Patients with other types of airway diseases or those not diagnosed with laryngotracheal stenosis may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for patients with laryngotracheal stenosis, potentially improving their breathing and quality of life.
How similar studies have performed: While targeting the mTOR pathway is a novel approach in this specific context, similar strategies have shown promise in other areas of regenerative medicine.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Hillel, Alexander — Johns Hopkins University
- Study coordinator: Hillel, Alexander
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.